Abstract
A total of 1587 patients with thyrotoxicosis (1387 women and 266 men) were examined over time after /sup 131/I therapy. The radioactive drug was given once to 808 patients, two times to 337 patients, 3 times to 198 and 4 times to 82 patients. 669 patients received 74-185 MBq of /sup 131/I. 649 patients 222-370 MBq, 128 patients 407-555 MBq and 94 patients 592-740 MBq. The other 47 patients received /sup 131/I of higher activity. Posttherapeutic hypothyrosis was revealed in 5.4% of the cases. In half of the patients hypothyrosis developed after a single administration of /sup 131/I. In all the patients with posttherapeutic hypothyrosis, i.v. administration of thyroliberin resulted in a significant rise of the thyrotropin level indicating to great importance of this test. A follow up of such patients is necessary as hypothyrosis can develop at different time after treatment of thyrotoxicosis patients with /sup 131/I.
Citation Formats
Khelds, A O, Ozols, V K, and Shtelmane, I A.
Delayed results of therapy of thyrotoxicosis with sup(131)I and posttherapeutic hypothyrosis.
USSR: N. p.,
1986.
Web.
Khelds, A O, Ozols, V K, & Shtelmane, I A.
Delayed results of therapy of thyrotoxicosis with sup(131)I and posttherapeutic hypothyrosis.
USSR.
Khelds, A O, Ozols, V K, and Shtelmane, I A.
1986.
"Delayed results of therapy of thyrotoxicosis with sup(131)I and posttherapeutic hypothyrosis."
USSR.
@misc{etde_6905532,
title = {Delayed results of therapy of thyrotoxicosis with sup(131)I and posttherapeutic hypothyrosis}
author = {Khelds, A O, Ozols, V K, and Shtelmane, I A}
abstractNote = {A total of 1587 patients with thyrotoxicosis (1387 women and 266 men) were examined over time after /sup 131/I therapy. The radioactive drug was given once to 808 patients, two times to 337 patients, 3 times to 198 and 4 times to 82 patients. 669 patients received 74-185 MBq of /sup 131/I. 649 patients 222-370 MBq, 128 patients 407-555 MBq and 94 patients 592-740 MBq. The other 47 patients received /sup 131/I of higher activity. Posttherapeutic hypothyrosis was revealed in 5.4% of the cases. In half of the patients hypothyrosis developed after a single administration of /sup 131/I. In all the patients with posttherapeutic hypothyrosis, i.v. administration of thyroliberin resulted in a significant rise of the thyrotropin level indicating to great importance of this test. A follow up of such patients is necessary as hypothyrosis can develop at different time after treatment of thyrotoxicosis patients with /sup 131/I.}
journal = []
volume = {31:3}
journal type = {AC}
place = {USSR}
year = {1986}
month = {Mar}
}
title = {Delayed results of therapy of thyrotoxicosis with sup(131)I and posttherapeutic hypothyrosis}
author = {Khelds, A O, Ozols, V K, and Shtelmane, I A}
abstractNote = {A total of 1587 patients with thyrotoxicosis (1387 women and 266 men) were examined over time after /sup 131/I therapy. The radioactive drug was given once to 808 patients, two times to 337 patients, 3 times to 198 and 4 times to 82 patients. 669 patients received 74-185 MBq of /sup 131/I. 649 patients 222-370 MBq, 128 patients 407-555 MBq and 94 patients 592-740 MBq. The other 47 patients received /sup 131/I of higher activity. Posttherapeutic hypothyrosis was revealed in 5.4% of the cases. In half of the patients hypothyrosis developed after a single administration of /sup 131/I. In all the patients with posttherapeutic hypothyrosis, i.v. administration of thyroliberin resulted in a significant rise of the thyrotropin level indicating to great importance of this test. A follow up of such patients is necessary as hypothyrosis can develop at different time after treatment of thyrotoxicosis patients with /sup 131/I.}
journal = []
volume = {31:3}
journal type = {AC}
place = {USSR}
year = {1986}
month = {Mar}
}